Duke Perspectives at AHA 2017

DUKE PERSPECTIVES
AHA Conference Coverage
November 11 to 15, 2017

Duke attended the American Heart Association's 2017 Scientific Sessions held November 11 to 15 in Anaheim, CA. Read what you may have missed in our daily recaps.

New Research Showcases Duke’s Commitment to Global Cardiology and Care in Kenya
November 14, 2017
New risk models and strategies for care are needed for cardiac disease in pregnant women in East Africa [Read more]

Insights From EXSCEL: A Risk-Modeling Analysis of the Effect of Once-Weekly Exenatide on Cardiovascular Outcomes
November 14, 2017
Does the effectiveness of once-weekly exenatide vary according to a patient’s baseline risk? [Read more]

Rapid Reversal of Dabigatran in Patients Requiring Emergency Surgery
November 14, 2017
A new analysis of the RE-VERSE AD study shows that idarucizumab achieves normal hemostasis in dabigatran-treated patients needing emergency surgery [Read more]

Racial Disparities Found in Anticoagulation of Atrial Fibrillation Patients in Large Cohort Analysis
November 15, 2017
Large percentages of atrial fibrillation patients with high stroke risk are discharged without anticoagulation [Read more]

Guideline on Ventricular Arrhythmias and Sudden Cardiac Death Prevention Is Updated for the First Time in 11 Years
November 15, 2017
The 2017 guideline includes the first use of value statements as well as recommendations for shared decision making and terminal care [Read more]

Regional Coordination Accelerates Reperfusion Times for Patients With STEMI in Trial Led by Duke and AHA
November 15, 2017
Time to reperfusion matters—faster treatment times can reduce mortality [Read more]

New Tools Are Available for Challenging Cases of Congenital Heart Disease
November 16, 2017
Novel devices are facilitating percutaneous treatment in patients with complex disease [Read more]

Epicardial Injections of Botulinum Toxin Evaluated to Prevent Postoperative Atrial Fibrillation
November 16, 2017
An innovative approach reduced the rate of postoperative atrial fibrillation and the duration of the first episode [Read more]

Mixed Findings From ALLSTAR Trial of Stem Cell Therapy After Myocardial Infarction
November 16, 2017
Patients “matched” for donor-specific antibodies did not reach the primary endpoint—but unmatched patients did [Read more]